#peripartum-cardiomyopathy #cardiomyopathy #heart-failure #pregnancy #genetics #maternal-health

Peripartum Cardiomyopathy

Details

Peripartum cardiomyopathy (PPCM) is defined as maternal heart failure with systolic dysfunction (LVEF <45%) developing in the last month of pregnancy or in the first 5 months after delivery, in the absence of known preexisting cardiac dysfunction or other identifiable reversible cause. It is a diagnosis of exclusion. PPCM and dilated cardiomyopathy (DCM) share an overlapping genetic spectrum, with pregnancy acting as an environmental "second hit" in susceptible women; their distinction is diagnostically important but sometimes challenging. sources/peripartum-cmp-nejm-2024 sources/cv-pregnancy-aha-2020

Epidemiology

Complicates ~1 in 2,000 births worldwide; highest rates in Haiti (~1/300) and parts of Nigeria (~1/100) sources/peripartum-cmp-nejm-2024 (rating: high)
In the US, Black women are 4× more likely to develop PPCM than White women; 2× more likely to have persistent dysfunction; recovery takes 2× as long sources/peripartum-cmp-nejm-2024 (rating: high)
One-third to one-half of cases co-occur with hypertensive disorders of pregnancy (including preeclampsia); preeclampsia aOR 3.3 for PPCM sources/peripartum-cmp-nejm-2024 sources/cv-pregnancy-aha-2020
Other strong risk factors: multiple gestations, advanced maternal age, anemia; mode of delivery is not a recognised risk factor
Leading cause of maternal death in many US regions; ~60% of cardiogenic shock in pregnancy/postpartum is due to PPCM; mortality up to 20%

Clinical Presentation

Symptoms and signs of HF: dyspnea, orthopnea, elevated JVP, pulmonary rales, peripheral oedema
Diagnosis frequently delayed — symptoms overlap with normal pregnancy physiology; high index of suspicion required
60–90% of cases occur after delivery, with peak incidence in the first postpartum week
Presentation can be acute and catastrophic (cardiogenic shock); arrhythmia or thromboembolic event may be the presenting feature
Black women in the US are more likely to present later in the postpartum period — contributing to worse outcomes

Diagnosis

Echocardiography: LVEF <45% + absence of other structural heart disease; LV dilatation common but not universal
BNP is usually elevated (unlike normal pregnancy where BNP is stable) — prompts evaluation but is not diagnostic
CMR: late gadolinium enhancement consistent with myocarditis is uncommon — argues against myocarditis as a primary mechanism
Endomyocardial biopsy: rarely needed or performed
Reversible causes to exclude: myocarditis, hypertension-related, underlying valve disease, toxin-induced (alcohol, chemotherapy), ischaemia, preeclampsia-induced pulmonary oedema without systolic dysfunction, PE, SCAD
Genetic testing should be offered to most patients, even without family history sources/peripartum-cmp-nejm-2024 (rating: high)
sources/cv-pregnancy-aha-2020 (rating: high)

Pathogenesis — Vasculohormonal Model

PPCM develops predominantly after delivery — temporally discordant with hemodynamic changes of pregnancy, arguing against a simple "failed hemodynamic stress test" hypothesis. Current model: peripartum hormonal imbalances damage the cardiac vasculature in genetically susceptible women. sources/peripartum-cmp-nejm-2024 (rating: high)

Pituitary-derived:

Prolactin: Cathepsin D cleaves prolactin to a 16-kDa cardiotoxic fragment → damages cardiac vasculature → ischaemia + paracrine signaling → endothelial cells secrete exosomes containing miR-146a → cardiomyocyte apoptosis. This is the mechanistic basis for bromocriptine therapy
Oxytocin: Secreted to promote lactation; vasculotoxic effects in Marfan syndrome models; definitive PPCM role not established

Placenta-derived:

sFlt-1 (soluble fms-like tyrosine kinase 1): Decoy receptor for VEGF, abundantly secreted by placental syncytiotrophoblasts in late gestation → cardiovascular rarefaction → PPCM in mice. Explains the epidemiological association with preeclampsia and multiple gestations (both associated with large increases in placental sFlt-1)
Activin A: Senescence-associated peptide from late-gestation placenta; correlates with subclinical cardiac dysfunction including 1 year post-delivery in preeclampsia
Progesterone: Suppresses cardiac carbohydrate oxidation (PDK4 upregulation), promotes cardiac hypertrophy, may have direct negative-inotropic effects — sensitises myocardium to further insults
Relaxin-2: Vasculoprotective hormone that is paradoxically suppressed in PPCM

Other hormonal signals: oestrogen, progesterone and FGF-21 fluctuate sharply peripartum and have been proposed as additional contributors to the metabolic and vascular insult. (sources/DCM-Lancet-2023, rating: very high)

Other proposed mechanisms (limited evidence): autoimmunity (anti-troponin I antibodies), microchimerism, inflammation, selenium deficiency (mainly parts of Nigeria)

Genetics

~15% of PPCM patients carry heterozygous loss-of-function variants in DCM-associated genes; variant frequencies are nearly identical to those in DCM — suggesting a shared genetic spectrum where pregnancy is an environmental second hit sources/peripartum-cmp-nejm-2024 (rating: high)
The same DCM-predisposing variants increase susceptibility to chemotherapy-induced and alcohol-induced cardiomyopathy — pointing to a common underlying cardiomyocyte vulnerability
TTN (titin): ~2/3 of identified genetic variants in PPCM; penetrance <5%; does not predict different prognosis
FLNC (filamin C) and DSP (desmoplakin): associated with ventricular arrhythmias in DCM; gene-specific arrhythmia risk stratification applies to PPCM carriers
Rare presentations: Danon's disease (LAMP2) and Duchenne's muscular dystrophy (DMD) can present first as PPCM
Cascade testing of family members is appropriate when a pathogenic variant is identified
In an international sequencing study of 469 women, over 10% carried TTNtvs, associated with a lower ejection fraction than other variants — but with no difference in timing of PPCM presentation, concomitant preeclampsia, or rate of clinical recovery among truncating variants. The variant predicts the severity of the initial hit, not the trajectory (sources/cmp-pregnancy-jaccadv-2026, rating: medium)
Genetic counselling and testing are recommended for all women with PPCM by both the 2025 ESC guideline and the cardio-obstetrics literature — yet in a recent study only 11% were referred for genetic evaluation. This is the largest implementation gap in the disease: a 1-in-7 diagnostic yield attached to a 1-in-9 referral rate
The wider DCM gene list applies — TTN, FLNC, DSP, MYH6, MYH7, BAG3 — and the finding of a variant reframes PPCM from an obstetric event to a familial cardiomyopathy requiring cascade screening

Management

BOARD Framework — Acute PPCM (ESC 2018)

Formalised acute PPCM management: sources/cv-pregnancy-esc-2018 (rating: very high)

Bromocriptine — dopamine agonist suppressing prolactin; 2.5 mg OD ≥1 week in uncomplicated cases (IIbB); 2.5 mg BID ×2 weeks → 2.5 mg OD ×6 weeks if EF <25% or cardiogenic shock (IIbB); always with anticoagulation
Oral HF therapies — ACEi/ARB/ARNI/MRA/ivabradine contraindicated in pregnancy and breastfeeding; hydralazine + isosorbide dinitrate as substitutes during pregnancy
Anticoagulants — standard indications; consider prophylactic anticoagulation if EF very low even without thrombus (IIaC); LMWH preferred
Relaxing agents — hydralazine/nitrates as vasodilators in context of hypertension/severe LV dysfunction/congestion
Diuretics — loop diuretics for congestion; avoid in uncongested patients (reduces placental perfusion)

Post-Delivery GDMT

ACEi/ARBs/aldosterone antagonists: initiate post-delivery; continue per HFrEF GDMT
Sacubitril-valsartan and SGLT2i: no formal pregnancy/breastfeeding safety data; increasingly used by extrapolation from HFrEF evidence
Most standard HF medications are compatible with breastfeeding; no safety data for ARNi/SGLT2i
Adrenergic agonists should be avoided in PPCM — low STAT3 sensitises to β-adrenergic toxicity; levosimendan preferred inotrope if needed sources/cv-pregnancy-esc-2018
Advanced therapies (IABP, percutaneous VAD, ECMO, LVAD) as appropriate given young age and frequent recovery potential; LVAD/transplant required in up to 10% of cases

Device Therapy

Wearable cardioverter-defibrillator (WCD): preferred over ICD when a defibrillator is indicated — cardiac function frequently recovers; protects during recovery window; avoids premature permanent ICD implantation (limited data; not tested specifically in pregnant patients) sources/cv-pregnancy-esc-2018
Permanent ICD: only after 6–12 months of optimal therapy without recovery; follows standard guidelines
CRT: indicated after 6–12 months if LBBB + QRS >130 ms despite optimal therapy

Bromocriptine Evidence

ESC guidelines recommend consideration in LVEF <35% (COR 2a); US expert consensus is less uniform
REBIRTH trial (NCT05180773; n=200; randomised vs placebo): expected to complete 2026; will be definitive
Published evidence: Sliwa 2010 (n=20; open-label proof-of-concept); Hilfiker-Kleiner 2017 (n=60; two dosing regimens, no placebo control); meta-analysis of available data suggests benefit but all studies have significant methodological limitations sources/peripartum-cmp-nejm-2024 (rating: high)
Always accompany bromocriptine with anticoagulation (LMWH at minimum prophylactic doses)

Medication Withdrawal

Cellular/molecular recovery lags echocardiographic recovery; contractile reserve abnormalities can persist despite normalised EF (parallel to TRED-HF experience in DCM)
Reasonable approach: wait ≥1 year after echocardiographic recovery, withdraw one agent at a time, with close long-term monitoring; no PPCM-specific withdrawal trial data exist

Breastfeeding

In severe HFrEF (NYHA III/IV), breastfeeding is discouraged; stopping lactation reduces metabolic demand and enables optimal HF treatment (IIbB) sources/cv-pregnancy-esc-2018
Bromocriptine as lactation inhibitor (and PPCM adjunct) is preferred over cabergoline in PPCM; always with anticoagulation

Prognosis

IPAC study (n=100): LV recovery occurred almost exclusively in the first 6 months postpartum; major cardiovascular events (transplantation, LVAD, death) occurred almost exclusively in women with EF <30% at presentation — EF at presentation is the critical high-risk threshold sources/cv-pregnancy-aha-2020 (rating: high)
50% of patients recover LVEF >50% within 6 months; some never recover; LVAD or transplantation in up to 10%; post-transplant survival inferior to age-matched recipients for other indications
Adverse outcome predictors: low LVEF at presentation, late presentation (>1 week post-delivery), LGE on CMR, LV dilatation, RV dysfunction
Co-occurring preeclampsia is paradoxically associated with better LV recovery but higher long-term adverse cardiovascular event rates
Long-term outcomes (>5 years) are poorly studied; mental health impact is substantial (up to 50% meet criteria for depression or PTSD)

mWHO Classification and Contraception

mWHO Classification

mWHO IV (40–100% maternal event rate; pregnancy not recommended): prior PPCM with any residual LV dysfunction sources/cv-pregnancy-esc-2018 (rating: very high)
Even with normalised EF, counselling required due to recurrence risk; subsequent pregnancy should be explicitly discouraged if LVEF does not normalise (IIIC)

Contraception

Contraception must be discussed early and before discharge: sources/cv-pregnancy-aha-2020 (rating: high)

IUD (copper or hormonal): reasonable in all PPCM (mild or severe dysfunction)
Progestin-only implant/pill: reasonable in all PPCM
Combined hormonal contraception (CHC): unreasonable even in PPCM with normal/mild systolic dysfunction — risk outweighs benefit

Subsequent Pregnancy

Recurrence rate 10–50%; recurrent episodes can be worse (including death)
Lack of LV recovery before subsequent pregnancy is associated with worse outcomes but is not a strong independent predictor
2025 ESC guideline: subsequent pregnancy discouraged when LV dysfunction persists (LVEF <50%) — but risk of recurrent dysfunction, life-threatening arrhythmia and rarely death continues even when EF has recovered ≥50%. There is no threshold below which the risk is zero (sources/cmp-pregnancy-jaccadv-2026, rating: medium)
Prospective European data (2025) suggest women with LVEF 40–50% may proceed under careful multidisciplinary monitoring — a more permissive position than the guideline, and one that affects a large group of partially recovered patients
Recovery status dominates outcome. In a US retrospective cohort of women with PPCM and a subsequent pregnancy (80% African American), non-recovered LVEF was associated with adverse outcomes in 53% versus 20% and 5-year all-cause mortality 13.3% versus 3.3% compared with recovered LVEF
Preconception package before a subsequent pregnancy: baseline echocardiogram, natriuretic peptide level, clinical assessment, and adjustment of medical therapy
Surveillance during a subsequent pregnancy: echocardiography and natriuretic peptide at the end of the first trimester, end of the second, 1 month before delivery, after delivery before discharge, 1 month postpartum, and at any point symptoms develop
Multidisciplinary monitoring during and after subsequent pregnancy is mandatory
Counselling must weigh uncertain risks against the patient's reproductive wishes

Contradictions / Open Questions

Bromocriptine clinical benefit: ESC COR 2a is based on small, non-placebo-controlled trials; US expert consensus less uniform; REBIRTH trial (2026) results will be definitive. Benefit must be weighed against stopping breastfeeding in resource-limited settings where cessation increases infant mortality >10-fold sources/peripartum-cmp-nejm-2024 sources/cv-pregnancy-aha-2020
PPCM vs DCM spectrum: Genetic frequencies nearly identical, yet clinical behaviour differs. Whether pregnancy is purely a trigger or also a disease modifier, and how long pregnancy-specific vulnerability persists, is unresolved sources/peripartum-cmp-nejm-2024
Racial disparities — mechanism: 4× higher incidence and 2× worse outcomes in US Black women; studies suggest socioeconomic factors (neighbourhood deprivation, provider bias) rather than genetics drive this inequity, but evidence is limited sources/peripartum-cmp-nejm-2024
Medication withdrawal timing: Extrapolated from TRED-HF (DCM); PPCM-specific withdrawal trial data do not exist sources/peripartum-cmp-nejm-2024
Anticoagulation threshold: No consensus on EF cutoff at which to initiate prophylactic anticoagulation in PPCM in the absence of intracardiac thrombus sources/cv-pregnancy-aha-2020
Future pregnancy risk quantification: Recurrence risk estimated at 20–50% depending on EF recovery; precise estimation not established sources/cv-pregnancy-aha-2020
Long-term prognosis: Very limited data beyond 5 years in this young patient population sources/peripartum-cmp-nejm-2024
"Recovered" has no agreed definition, and every subsequent-pregnancy rule turns on it. ESC 2025 draws the line at LVEF <50%; prospective European data suggest 40–50% may proceed; the US cohort shows a 2.7-fold adverse outcome rate in non-recovered women. A patient at exactly 50% satisfies all three rules at once, with different advice from each. (sources/cmp-pregnancy-jaccadv-2026, rating: medium)
The genetic recommendation and the referral rate are irreconcilable. Testing all PPCM patients is guideline-endorsed with a >10% yield, and 89% are not referred. Whether this reflects access, cost, clinicians not regarding PPCM as a genetic disease, or patients declining is untested — and until it is, the recommendation is nominal.

Connections

Related to entities/DCM — shared genetic spectrum (TTN, FLNC, DSP, LAMP2, DMD); PPCM as DCM triggered by pregnancy hormones
Related to concepts/Hypertensive-Disorders-of-Pregnancy — preeclampsia co-occurs in 1/3–1/2 of PPCM; sFlt-1 as shared mechanistic link
Related to concepts/Cardio-Obstetrics — PPCM is the cardiomyopathy most directly managed by the cardio-obstetrics team
Related to entities/Heart-Failure — PPCM management follows HF principles with pregnancy-specific adaptations
Related to entities/Maternal-Health-Disparities — racial disparities in PPCM incidence and outcomes
Related to concepts/Adverse-Pregnancy-Outcomes — PPCM as an adverse cardiovascular outcome of pregnancy
Related to concepts/Preeclampsia — preeclampsia aOR 3.3 for PPCM; sFlt-1 shared mechanism
Related to entities/TTN — most common genetic predisposition (~2/3 of genetic PPCM cases)
Related to entities/FLNC — arrhythmia risk in PPCM
Related to entities/DSP — arrhythmia risk in PPCM
Related to concepts/Pregnancy-in-Genetic-Cardiomyopathy — PPCM as the genetic cardiomyopathy with the most specific pregnancy rules
Related to concepts/mWHO-Classification — any residual dysfunction = mWHO IV